ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
Ye, Mingxiang, Zhang, Xinxin, Li, Nan, Zhang, Yong, Jing, Pengyu, Chang, Ning, Wu, Jianxiong, Ren, Xinling, Zhang, JianVolume:
7
Journal:
Oncotarget
DOI:
10.18632/oncotarget.6935
Date:
March, 2016
File:
PDF, 1.73 MB
2016